Tracers / [89Zr]PEG-Nb159
[89Zr]PEG-Nb159
- Radionuclide
- Zr-89 t½ 4704 min
- Modality
- Therapy
- Production route
- —
- Stage
- Reported once
- Syntheses indexed
- 1
What it is
- Compound class
- FAP-targeting nanobody conjugated with DFO and PEG
- Target / mechanism
- Fibroblast activation protein (FAP) PMID 41460404
- Clinical application
- PET imaging companion diagnostic for FAP-targeted radiotheranostics, preclinical mouse tumor model PMID 41460404
- Theranostic pair
- <a href="/tracers/lu177-pegnb159/">lu177-pegnb159</a>
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | SPE | — | — | PEG-DFO-Nb159 | 41460404 2025 EJNMMI Radiopharm Chem 111 MBq of 89Zr-oxalate solution (3D Imaging) was diluted with 300 µl of 1 M HEPES and added to 200 µl of DFO-functionalized Nb (1–2 mg) in HEPES/NaCl buffer (pH 7.5), adjusted to pH 6.8–7.5, and incubated for 1 h at room temperature. |
Need this precursor?We can point you to suppliers for [89Zr]PEG-Nb159, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 41460404. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 41460404: 'PEG-DFO-Nb159'.